The recent decision by the Food and Drug Administration (FDA) marks a significant shift in how new drugs will be evaluated and approved. Under the new plan, FDA Commissioner Dr. Marty Makary and his team, including Dr. Vinay Prasad, have announced they will largely abandon the longstanding requirement for two rigorous studies for new drugs. Instead, they will adopt a “default position” of needing only one study for approval in many cases. This change is part of a broader initiative aimed at streamlining the drug approval process and making medical products available more quickly.
The FDA’s updated approach reflects a growing recognition that scientific advancements have made drug research more precise. As Makary and Prasad noted in their piece published in the New England Journal of Medicine, “In this setting, overreliance on two trials no longer makes sense.” They predict that this policy shift will likely result in “a surge in drug development,” enabling quicker access for patients to potentially life-saving treatments.
Dr. Janet Woodcock, a veteran of the FDA who previously led the agency’s drug center, supports this move. She pointed out that the FDA has gradually shifted towards accepting single trials in cases of life-threatening diseases for many years. Woodcock emphasized that as understanding of biology and disease improves, the necessity of conducting two trials becomes less rigid. “The scientific point is well taken,” she stated.
Historically, the two-study requirement has its roots in legislation passed in the early 1960s. At that time, Congress mandated that the FDA only approve drugs based on what it deemed “adequate and well-controlled investigations.” The idea was simple: requiring two studies would help ensure that the results from the first study could be replicated and were not merely chance occurrences. However, beginning in the 1990s, the FDA started to accept single studies for rare or fatal diseases—those drugs typically hampered by smaller patient populations and greater challenges in recruitment.
Notably, the recent trend has shown that about 60 percent of first-of-a-kind drugs have already gained approval based on just one study in the past five years. This reflects broader changes in legislation encouraging regulators to exhibit flexibility, particularly for drugs that address serious or challenging conditions.
It’s essential to note that the new guidelines will primarily impact common diseases rather than the cancers and rare diseases that have already benefited from this relaxed standard. Woodcock clarified, “It’s not the cancers and the rare diseases that will be affected by this.” The FDA has been allowing approval based on a single trial in those cases for some time.
However, there is a noticeable contrast between this new approach and the agency’s handling of other products, such as vaccines and gene therapies. Recently, the FDA’s vaccine division, overseen by Prasad, denied Moderna’s application for a new mRNA flu shot due to perceived insufficiencies in clinical trials. Shortly after, the agency reversed its decision, agreeing to review the vaccine contingent on an additional study being performed in older populations. This inconsistency raises questions about the agency’s overall direction in balancing the goals of speed and safety in drug approval.
Moreover, Prasad has taken a cautious stance on several experimental gene therapies, turning down applications that lack thorough supporting evidence or additional studies. This cautious approach has led to some strain among biotech firms, resulting in declining stock prices and apprehension regarding the future of their products and therapies.
As Woodcock astutely observes, the true test of this policy change will hinge on how it is implemented. The FDA’s evolving stance creates a climate of uncertainty within the industry. She remarked, “Implementation will be everything,” indicating that the clarity of the FDA’s approach moving forward remains uncertain. This lack of clarity has left companies bewildered.
As the FDA’s methods continue to evolve, it remains to be seen how they will strike a balance between innovation and thorough evaluation, and whether this latest change will truly accelerate access to necessary medications or muddle the approval landscape further. The industry will watch closely as these developments unfold, keeping a keen eye on how the FDA navigates the complexities of urgent patient needs and rigorous scientific standards.
"*" indicates required fields
